Search Medical Condition
Please enter condition
Please choose location

Trujillo Alto, Puerto Rico Clinical Trials

A listing of Trujillo Alto, Puerto Rico clinical trials actively recruiting patients volunteers.

RESULTS

Found (120) clinical trials

The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or metastatic HER2-negative breast cancer who are resistant to or have failed prior taxane and an anthracycline ...

Phase

2.06 miles

Learn More »

This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the body. Sorafenib tosylate may stop ...

Phase

2.06 miles

Learn More »

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ...

Phase

2.06 miles

Learn More »

Apheresis and Specimen Collection Procedures to Obtain Plasma Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

Protocol Design: This protocol is designed to perform collection of human specimens, such as blood, mucosal secretions, skin swabs, skin biopsy, or body fluids to support research studies. These samples will be used by laboratory researches in their work on the development of vaccines for HIV and other infectious diseases, ...

Phase N/A

3.24 miles

Learn More »

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

Despite the substantial number of work published over the past years in different populations around the world, a fundamental gap remains in understanding whether and how genomic admixture and polymorphisms in warfarin-related pharmacogenes account for the high inter-individual dose variability observed in Caribbean Hispanic patients. In addition to being a ...

Phase N/A

3.78 miles

Learn More »

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

The purpose of this study is to determine if an investigational treatment is effective compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.

Phase

3.78 miles

Learn More »

Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo

The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.

Phase

3.78 miles

Learn More »

Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects

This study will consist of three study periods as follows: 1. Screening Period of up to 6 weeks (8 weeks if on Mircera) 2. Treatment Period: a minimum of 52 weeks, a maximum of up to 3 years. 3. A Follow-up period of 4 weeks. A total of up to ...

Phase

4.13 miles

Learn More »

Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder

Study LVM-MD-11 is a randomized, double-blind, placebo- and active-controlled, parallel group, fixed-dose study in adolescent patients, ages 12-17 years. The study will be approximately 10 weeks in duration: - 1-week screening/washout period - 8-week double-blind treatment period - 1-week double-blind down-taper period Patients who meet the eligibility criteria at Visit ...

Phase

4.13 miles

Learn More »

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Patients With Bipolar I Disorder

This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 mg/day or 3 mg/day compared to placebo for treatment of the depressive episode in patients with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

Phase

4.13 miles

Learn More »